All articles by Phillip Broadwith – Page 12
-
Business
AstraZeneca sells off drugs to streamline portfolio
Crohn’s disease and rare thyroid cancer drugs lie outside firm’s renewed strategic focus
-
Business
Lightweight composites drive Solvay to buy Cytec
$5.5bn deal launches Solvay into aerospace materials business
-
Business
Celgene to buy immune-inflammatory specialist Receptos
$7.2bn deal further strengthens Celgene’s position in immunology
-
Business
Hikma boosts generics with Roxane buyout
Acquiring the Boehringer Ingelheim subsidiary expands Hikma’s presence in US generics market
-
Business
Biogen to develop gene therapies with AGTC
$1bn deal gives Biogen rights to one clinical candidate and several earlier-stage programmes for rare eye diseases
-
Business
Three dead in Chinese petrochemical plant fire
Further four workers injured after leaking oil ignited at Qingyang Petrochemical plant in Gansu province
-
Opinion
Taking responsibility seriously
Companies have a duty to be proactive when it comes to sustainability
-
BusinessAn unsustainable hypocrisy
Social responsibility should extend through the whole supply chain, not just be a tool to put pressure on feedstock suppliers
-
Business
Celgene backs immunotherapy with Juno collaboration
$1bn investment in 10-year CAR-T cell partnership for cancer treatments
-
Business
Thermo Fisher to buy Alfa Aesar chemical supplies
Research chemicals business no longer a strategic fit for owner Johnson Matthey
-
Business
Blast kills six at South Korean chemical plant
One further worker injured as tank explodes during welding work
-
Business
Job cuts at Allergan and Transgene
Allergan is shedding 300 staff at former Actavis site in Iceland, while Transgene is closing its French manufacturing plant with loss of 120 jobs
-
Business
Fracking prohibited in New York state and Lancashire
Local US and UK rulings prohibit shale oil drilling and exploration
-
ResearchCollaboration, not competition
Organic chemist E J Corey talks to Phillip Broadwith about awards, ambition and academic freedom
-
Business
Vertex nabs rights to cystic fibrosis molecules
Deal with Parion, worth up to $1bn, gives firm worldwide rights to investigational treatments that complement Vertex’s existing cystic fibrosis drugs
-
Business
Opko deepens diagnostics with $1.5bn lab buyout
Taking over clinical diagnostics service provider BioReference Laboratories gives Opko a bigger avenue to distribute and market its diagnostic tests
-
Business
Takeda to consolidate vaccines business in Boston
Firm will close three recently-acquired US sites and shift operations to the growing pharmaceutical hub in Massachusetts
-
Business
OM Group to be sold and split
Apollo Global Management will buy the firm for $1bn, then sell electronic materials business to Platform Specialty Products
-
Business
Teva fined $1.2bn in pay-for-delay case
Company illegally blocked generic competition of sleep disorder drug, and settlement terms tighten up rules on anticompetitive behaviour